Startseite>>Peptides>> Amyloid β protein>>Amyloid-β (17-40) Peptide (human) (trifluoroacetate salt)

Amyloid-β (17-40) Peptide (human) (trifluoroacetate salt) (Synonyms: Aβ (17-40))

Katalog-Nr.GC42799

Amyloid-β (Aβ) (17-40) is a 24-residue fragment of the Aβ protein that is formed via post-translational processing of amyloid precursor protein (APP) by α- and γ-secretases.

Products are for research use only. Not for human use. We do not sell to patients.

Amyloid-β (17-40) Peptide (human) (trifluoroacetate salt) Chemische Struktur

Größe Preis Lagerbestand Menge
500μg
339,00 $
Auf Lager
1mg
645,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Amyloid-β (Aβ) (17-40) is a 24-residue fragment of the Aβ protein that is formed via post-translational processing of amyloid precursor protein (APP) by α- and γ-secretases. In vitro, Aβ (17-40) polymerizes into lattice-like structures that do not bind thioflavin T. It inhibits interactions between fibrinogen and biotinylated Aβ (1-42) as well as between cholesterol and apolipoprotein E (ApoE) with IC50 values of 13.4 and 25 μM, respectively. Aβ (17-40) increases the rate of Aβ (1-40) aggregation in vitro when used at an equimolar concentration. Aβ (17-40) (25 μM) induces cell death in cultured rat hippocampal neurons.

Bewertungen

Review for Amyloid-β (17-40) Peptide (human) (trifluoroacetate salt)

Average Rating: 5 ★★★★★ (Based on Reviews and 14 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Amyloid-β (17-40) Peptide (human) (trifluoroacetate salt)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.